Castle Biosciences Stock Investor Sentiment
| CSTL Stock | USD 16.72 0.18 1.09% |
About 60% of all Castle Biosciences' institutional investors are looking to take a long position. The analysis of the overall investor sentiment regarding Castle Biosciences suggests that some traders are interested. Castle Biosciences' investing sentiment shows overall attitude of investors towards Castle Biosciences.
Comfort Level 60
Interested
Panic | Confidence |
Today, several news technology companies offer sentiment data to assist traders in manufacturing news sentiment indicators for investment decisions. We partner with these technology firms in helping retail investors build forecasting models that use Castle Biosciences' input sentiment indicators derived from textual data and news published on major financial information outlets and social sites. These indicators can be used to analyze time-dependent numerical information representing public perception toward Castle Biosciences.
News SentimentBullish | Hype SentimentNeutral | Insider SentimentDisposing |
Castle Historical Sentiment
Although Castle Biosciences' investment sentiment alone cannot always predict changes in its future share prices, when combined with other fundamental and technical analysis, a better chance to time the market can be gained. Certain informational and emotional events regarding Castle, such as negative comments on social media and news outlets, may cause fear in the market and push Castle Biosciences' investors to sell their holdings. The opposite can also be true when favorable news is released; it may translate into optimism and boost the price of Castle.
Castle Biosciences Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Castle Biosciences can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Castle Biosciences Historical Investor Sentiment
Investor biases related to Castle Biosciences' public news can be used to forecast risks associated with an investment in Castle. The trend in average sentiment can be used to explain how an investor holding Castle can time the market purely based on public headlines and social activities around Castle Biosciences. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Castle Biosciences' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Castle Biosciences and other traded tickers. The bigger the bubble, the more accurate the estimated score. Higher bars for a given day show more participation in the average Castle Biosciences news discussions. The higher the estimate score, the more favorable the investor's outlook on Castle Biosciences.
Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of Castle Biosciences' Stock prices. Below is the latest headlines and news related to Castle Biosciences Stock. Current markets are slightly bullish. About 55% of major world exchanges and indexes are currently up. See today's market update for more information.
There is far too much social signal, news, headlines, and media speculation about Castle Biosciences that are available to investors today. This information is accessible both publicly - through Castle Biosciences' media outlets and privately, via word of mouth or internal channels. However, regardless of the source, the sheer volume of Castle-related data is difficult to distill into actionable insights, especially for investors who are not well-versed in the rapidly evolving tools and techniques of investment management.
A primary focus of Castle Biosciences news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Castle Biosciences relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Castle Biosciences' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Castle Biosciences alpha.
Castle Largest EPS Surprises
Earnings surprises can significantly impact Castle Biosciences' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2021-03-08 | 2020-12-31 | -0.12 | -0.17 | -0.05 | 41 | ||
2021-05-10 | 2021-03-31 | -0.23 | -0.17 | 0.06 | 26 | ||
2021-11-08 | 2021-09-30 | -0.4 | -0.47 | -0.07 | 17 | ||
2022-11-02 | 2022-09-30 | -0.88 | -0.77 | 0.11 | 12 | ||
2020-11-09 | 2020-09-30 | -0.11 | -0.23 | -0.12 | 109 | ||
2024-11-04 | 2024-09-30 | -0.06 | 0.08 | 0.14 | 233 |
There is far too much social signal, news, headlines, and media speculation about Castle Biosciences that are available to investors today. This information is accessible both publicly - through Castle Biosciences' media outlets and privately, via word of mouth or internal channels. However, regardless of the source, the sheer volume of Castle-related data is difficult to distill into actionable insights, especially for investors who are not well-versed in the rapidly evolving tools and techniques of investment management.
A primary focus of Castle Biosciences news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Castle Biosciences relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Castle Biosciences' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Castle Biosciences alpha.
Castle Biosciences Performance against Dow Jones
Price Growth (%) |
| Timeline |
1 | New Data at DDW 2025 Further Demonstrates the TissueCypher Tests Ability to Identify Patients at Increased Risk for Developing Esophageal Cancer | 05/02/2025 |
2 | Castle Biosciences First Quarter 2025 Earnings Revenues Beat Expectations, EPS Lags | 05/07/2025 |
3 | Acquisition by Cotton Rodney of 1952 shares of Castle Biosciences subject to Rule 16b-3 | 05/08/2025 |
4 | Disposition of tradable shares by Derek Maetzold of Castle Biosciences at 29.48 subject to Rule 16b-3 | 05/15/2025 |
5 | Castle Biosciences to Present at the 2025 Jefferies Global Healthcare Conference | 05/21/2025 |
6 | Acquisition by Harrison Miles of 13667 shares of Castle Biosciences subject to Rule 16b-3 | 05/22/2025 |
7 | Castle Biosciences Founder, President and CEO Derek Maetzold Honored with Prestigious Lifetime Achievement Award by The American Business Awards | 06/04/2025 |
8 | Castle Biosciences Chief Executive Officer Derek Maetzold to Participate in Panel Discussion ... | 06/11/2025 |
9 | Castle Biosciences Enters Collaboration and License Agreement with SciBase to Develop ... | 06/16/2025 |
10 | SciBase has signed a Collaboration and License Agreement with Castle Biosciences to develop diagnostic tests within dermatology and intends to carry out a direc... | 06/17/2025 |
11 | Castle Biosciences to Release Second Quarter 2025 Financial Results and Host Conference Call on Monday, Aug. 4, 2025 | 07/14/2025 |
12 | Castle Biosciences Honored with Multiple Top Workplaces Awards Recognizing the Companys Strong ... | 07/17/2025 |
Check out Castle Biosciences Hype Analysis, Castle Biosciences Correlation and Castle Biosciences Performance. For more information on how to buy Castle Stock please use our How to buy in Castle Stock guide.You can also try the Equity Valuation module to check real value of public entities based on technical and fundamental data.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Castle Biosciences. If investors know Castle will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Castle Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.93) | Earnings Share (0.19) | Revenue Per Share | Quarterly Revenue Growth 0.206 | Return On Assets |
The market value of Castle Biosciences is measured differently than its book value, which is the value of Castle that is recorded on the company's balance sheet. Investors also form their own opinion of Castle Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Castle Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Castle Biosciences' market value can be influenced by many factors that don't directly affect Castle Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Castle Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Castle Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Castle Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.